drugset / Trial / NCT06723964
A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of AP505 injection in patients with advanced solid tumors. The study will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for AP505.
Timeline
- Start
- 2023-03-30
- Primary completion
- 2024-10-31
- Completion
- 2025-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AP505 | Unknown | 0.035 mg/kg | — |
| Subject | AP505 | Unknown | 0.12 mg/kg | — |
| Subject | AP505 | Unknown | 0.4 mg/kg | — |
| Subject | AP505 | Unknown | 1.2 mg/kg | — |
| Subject | AP505 | Unknown | 4 mg/kg | — |
| Subject | AP505 | Unknown | 8 mg/kg | — |
| Subject | AP505 | Unknown | 11 mg/kg | — |
| Subject | AP505 | Unknown | 15 mg/kg | — |
| Subject | AP505 | Unknown | 20 mg/kg | — |
| Subject | AP505 | Unknown | 25 mg/kg | — |